Indication

Relapsed Advanced Lymphomas

1 clinical trial

1 product

Clinical trial

A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients With Relapsed Advanced Lymphomas(ASHA-1)

Status: Recruiting, Estimated PCD: 2025-08-30

Product